Sign In
Get Clay Free →

Suggestions

    Philipp Jaeger

    Scientific Director at Boehringer Ingelheim

    Professional Background

    Dr. Philipp Jaeger is a distinguished scientist and leader in the field of drug discovery, with a specific focus on high-throughput biology. As the Scientific Director of High-Throughput Biology at Boehringer Ingelheim, his work prioritizes patient outcomes by employing innovative methodologies to enhance the drug discovery workflow. Driven by a passion for integrating advanced biochemical, biophysical, and cellular assays, Dr. Jaeger expertly leads a multidisciplinary team of up to 25 researchers, continuously seeking to unlock biological relevance from the myriad of hypotheses tested in the lab.

    With over 15 years of research experience coupled with 5 years in start-up and industry environments, he combines his extensive knowledge in systems biology, programming, and statistics to accelerate research and development (R&D). His approach focuses not just on innovation but also on ensuring that promising research translates seamlessly into reliable pre-clinical and pre-production pipelines, setting the stage for future clinical success.

    Dr. Jaeger has co-authored a total of 16 peer-reviewed journal articles and book chapters, showcasing his commitment to advancing scientific knowledge and contributing to the academic community. His collaborative spirit has also led him to write successful grant applications and participate in several patent applications, thereby underscoring his dedication to driving forward the frontiers of biomedical research.

    Education and Achievements

    Dr. Jaeger's educational background is as impressive as his professional career. He has undergone rigorous training in Biochemistry and Neuroscience through institutions renowned for their research contributions. His academic journey began at the University of Hamburg, where he obtained his Vordiplom in Biochemistry. He continued at the Freie Universität Berlin, completing his Dipl.-Biochem and furthering his studies with a Dr. rer. nat in Biochemistry.

    His pursuit of knowledge took him to the Humboldt-Universität zu Berlin for graduate studies in Neuroscience before embarking on PhD training at Stanford University, focusing on key neurological studies, including autophagy and protein signaling relating to Alzheimer's disease in the Wyss-Coray Lab. His expertise was further enhanced through postdoctoral research in Systems Biology at the University of California, San Diego, where he contributed significantly to understanding complex biological systems in yeast and humans.

    Across these esteemed institutions, Dr. Jaeger not only honed his scientific skills but also built a network of expertise that has proven invaluable in his career.

    Achievements

    Among his numerous achievements, Dr. Jaeger's leadership in High-Throughput Biology stands out as a critical role that influences the methodologies employed in drug discovery at Boehringer Ingelheim. His background in systems biology and experience with fast-paced R&D environments allow him to drive the development of innovative biological assays like cellular assays that are crucial for the success of drug discovery projects.

    His previous role as Laboratory Head in the Cellular Assays Lab at Boehringer Ingelheim and earlier positions at Encodia, Inc. highlight his extensive experience in assay development, where he demonstrated his ability to lead teams effectively. His responsibilities as both Senior Scientist and earlier roles like Scientist II equipped him with the critical tools necessary to navigate the complex landscape of drug discovery and development.

    His entrepreneurial spirit emerged early in his career with the founding of BiocipherX, Inc., where he explored novel approaches in phenotype screening and drug discovery, further cementing his status as an innovator in the life sciences. Dr. Jaeger's contributions extend beyond the lab; through his successful grant writer expertise, he has secured funding for vital research pursuits, thereby fostering continued advancement in drug discovery methodologies.

    Conclusion

    In summary, Dr. Philipp Jaeger exemplifies the intersection of advanced research and clinical application in the pharmaceutical industry. His dual focus on scientific rigor and patient-centered outcomes establishes him as a leading figure in the realm of drug discovery. His extensive educational background and comprehensive professional experience make him a driving force in the advancement of high-throughput biological methods and their application in developing drugs that can significantly improve patient care.

    tags':['drug discovery','biochemical assays','systems biology','high-throughput biology','biophysics','clinical research','neuroscience','biochemistry','R&D management','peer-reviewed publications','patent applications','team leadership','assay development','grant writing','biomedical research'],

    :

    questions':['How did Philipp Jaeger integrate his knowledge of biochemistry and neuroscience into his drug discovery processes at Boehringer Ingelheim?','What strategies did Philipp Jaeger use to effectively lead multidisciplinary teams in challenging environments?','How has Philipp Jaeger contributed to advancing drug discovery methods through his research and publications?','What influenced Philipp Jaeger’s decision to focus on high-throughput biology in the pharmaceutical industry?','How does Philipp Jaeger ensure that his team maintains a focus on clinical success from the outset of drug discovery projects?','In what ways does Philipp Jaeger’s academic background inform his leadership style in scientific research?'],

    :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title :

    title : I am delighted to present the combination of educational prowess and extensive experience that position Philipp Jaeger as a pioneering voice in drug discovery and high-throughput biology. With the depth in biochemistry and neuroscience complemented by a visionary outlook, his contributions to the field are invaluable. Engaging in a physiology of discovery, his work aligns with continual advancements that promise to yield beneficial developments in clinical settings.

    Philipp Jaeger
    Add to my network

    Location

    Vienna, Vienna, Austria